The liver is a highly metastasis-permissive organ, tumor seeding of which usually portends mortality. Its unique and diverse architectural and cellular composition enable the liver to undertake numerous specialized functions, however, this distinctive biology, notably its hemodynamic features and unique microenvironment, renders the liver intrinsically hospitable to disseminated tumor cells. The particular focus for this perspective is the bidirectional interactions between the disseminated tumor cells and the unique resident cell populations of the liver; notably, parenchymal hepatocytes and non-parenchymal liver sinusoidal endothelial, Kupffer, and hepatic stellate cells. Understanding the early steps in the metastatic seeding, including the decision to undergo dormancy versus outgrowth, has been difficult to study in 2D culture systems and animals due to numerous limitations. In response, tissue-engineered biomimetic systems have emerged. At the cutting-edge of these developments are ex vivo ‘microphysiological systems’ (MPS) which are cellular constructs designed to faithfully recapitulate the structure and function of a human organ or organ regions on a milli- to micro-scale level and can be made all human to maintain species-specific interactions. Hepatic MPSs are particularly attractive for studying metastases as in addition to the liver being a main site of metastatic seeding, it is also the principal site of drug metabolism and therapy-limiting toxicities. Thus, using these hepatic MPSs will enable not only an enhanced understanding of the fundamental aspects of metastasis but also allow for therapeutic agents to be fully studied for efficacy while also monitoring pharmacologic aspects and predicting toxicities. The review discusses some of the hepatic MPS models currently available and although only one MPS has been validated to relevantly modeling metastasis, it is anticipated that the adaptation of the other hepatic models to include tumors will not be long in coming.
EarlamSGloverCFordyCBurkeDAllen-MershTG. Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol1996; 14: 171–5.
7.
PickrenJTsukadaYLaneWLiver metastases: Analysis of autopsy data. In: WeissLGilbertH (eds). Liver metastases, Boston, MA: GK Hall Medical Publishers, 1982, pp. 2–18.
8.
GilbertHAKaganARHintzBLRaoARNussbaumHPatterns of metastases. In: WeissLHG (ed). Liver metastases, Boston, MA: GK Hall Medical Publishers, 1982, pp. 19–39.
9.
KmiecZ. Cooperation of liver cells in health and disease. Adv Anat EmbryolCell Biol2001; 161: III–XIII, 1–151.
10.
Vidal-VanaclochaFArchitectural and functional aspects of the liver with implications for cancer metastasis. In: BrodtP (ed). Liver metastasis: biology and clinical management, 1st ed. Netherlands: Springer, 2011, pp. 9–42.
11.
ChafferCLWeinbergRA. A perspective on cancer cell metastasis. Science2011; 331: 1559–64.
12.
KalluriRWeinbergRA. The basics of epithelial-mesenchymal transition. J Clin Investig2009; 119: 1420–8.
13.
NietoMA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science2013; 342: 1234850–1234850.
14.
WellsAYatesCShepardCR. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis2008; 25: 621–8.
15.
GunasingheNPWellsAThompsonEWHugoHJ. Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev2012; 31: 469–78.
16.
WellsAGrahovacJWheelerSMaBLauffenburgerD. Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol Sci2013; 34: 283–9.
17.
ChaoYWuQAcquafondataMDhirRWellsA. Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. Cancer Microenviron2012; 5: 19–28.
18.
WeidleUHBirzeleFKrugerA. Molecular targets and pathways involved in liver metastasis of colorectal cancer. Clin Exp Metastasis2015; 32: 623–35.
19.
MaRFengYLinSChenJLinHLiangXZhengHCaiX. Mechanisms involved in breast cancer liver metastasis. J Transl Med2015; 13: 64–64.
20.
ShiHLiJFuD. Process of hepatic metastasis from pancreatic cancer: biology with clinical significance. J Cancer Res Clin Oncol2016; 142: 1137–61.
21.
Vidal-VanaclochaF. The prometastatic microenvironment of the liver. Cancer Microenviron2008; 1: 113–29.
22.
JoyceJAPollardJW. Microenvironmental regulation of metastasis. Nat Rev Cancer2009; 9: 239–52.
23.
KienastYvon BaumgartenLFuhrmannMKlinkertWEGoldbrunnerRHermsJWinklerF. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med2010; 16: 116–22.
24.
LuzziKJMacDonaldICSchmidtEEKerkvlietNMorrisVLChambersAFGroomAC. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol1998; 153: 865–73.
25.
FidlerIJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer2003; 3: 453–8.
26.
IngberDE. Can cancer be reversed by engineering the tumor microenvironment?Semin Cancer Biol2008; 18: 356–64.
27.
BrooksSALomax-BrowneHJCarterTMKinchCEHallDM. Molecular interactions in cancer cell metastasis. Acta Histochem2010; 112: 3–25.
BraetFNagatsumaKSaitoMSoonLWisseEMatsuuraT. The hepatic sinusoidal endothelial lining and colorectal liver metastases. World J Gastroenterol2007; 13: 821–5.
30.
HehlgansTPfefferK. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology2005; 115: 1–20.
31.
WangHHMcIntoshARHasinoffBBRectorESAhmedNNanceDMOrrFW. B16 melanoma cell arrest in the mouse liver induces nitric oxide release and sinusoidal cytotoxicity: a natural hepatic defense against metastasis. Cancer Res2000; 60: 5862–9.
32.
YanagidaHKaiboriMYoshidaHHabaraKYamadaMKamiyamaYOkumuraT. Hepatic ischemia/reperfusion upregulates the susceptibility of hepatocytes to confer the induction of inducible nitric oxide synthase gene expression. Shock2006; 26: 162–8.
33.
JansenSAndriesMVekemansKVanbilloenHVerbruggenABollenM. Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. Cancer Lett2009; 284: 216–21.
34.
AaronsCBBajenovaOAndrewsCHeydrickSBushellKNReedKLThomasPBeckerJMStucchiAF. Carcinoembryonic antigen-stimulated THP-1 macrophages activate endothelial cells and increase cell-cell adhesion of colorectal cancer cells. Clin Exp Metastasis2007; 24: 201–9.
35.
AugustePFallavollitaLWangNBurnierJBikfalviABrodtP. The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. Am J Pathol2007; 170: 1781–92.
36.
GangopadhyayALazureDAThomasP. Adhesion of colorectal carcinoma cells to the endothelium is mediated by cytokines from CEA stimulated Kupffer cells. Clin Exp Metastasis1998; 16: 703–12.
37.
KhatibAMAugustePFallavollitaLWangNSamaniAKontogianneaMMeterissianSBrodtP. Characterization of the host proinflammatory response to tumor cells during the initial stages of liver metastasis. Am J Pathol2005; 167: 749–59.
38.
LaferriereJHouleFTaherMMValerieKHuotJ. Transendothelial migration of colon carcinoma cells requires expression of E-selectin by endothelial cells and activation of stress-activated protein kinase-2 (SAPK2/p38) in the tumor cells. J Biol Chem2001; 276: 33762–72.
39.
Arteta B, Lasuen N, Lopategi A, Sveinbjornsson B, Smedsrod B, Vidal-Vanaclocha F. Colon carcinoma cell interaction with liver sinusoidal endothelium inhibits organ-specific antitumor immunity through interleukin-1-induced mannose receptor in mice. Hepatology 2010;51:2172–82.
40.
EnomotoKNishikawaYOmoriYTokairinTYoshidaMOhiNNishimuraTYamamotoYLiQ. Cell biology and pathology of liver sinusoidal endothelial cells. Med Electron Microsc2004; 37: 208–15.
41.
FridmanRGiacconeGKanemotoTMartinGRGazdarAFMulshineJL. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci USA1990; 87: 6698–702.
42.
PascoSRamontLMaquartFXMonboisseJC. Control of melanoma progression by various matrikines from basement membrane macromolecules. Crit Rev Oncol/Hematol2004; 49: 221–33.
43.
SchenkSHintermannEBilbanMKoshikawaNHojillaCKhokhaRQuarantaV. Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. J Cell Biol2003; 161: 197–209.
44.
SchenkSQuarantaV. Tales from the crypt[ic] sites of the extracellular matrix. Trends Cell Biol2003; 13: 366–75.
45.
SwindleCSTranKTJohnsonTDBanerjeePMayesAMGriffithLWellsA. Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol2001; 154: 459–68.
46.
GrahovacJBeckerDWellsA. Melanoma cell invasiveness is promoted at least in part by the epidermal growth factor-like repeats of tenascin-C. J Invest Dermatol2013; 133: 210–20.
47.
GrahovacJWellsA. Matrikine and matricellular regulators of EGF receptor signaling on cancer cell migration and invasion. Lab Invest2014; 94: 31–40.
48.
RodriguesMYatesCCNuschkeAGriffithLWellsA. The matrikine tenascin-C protects multipotential stromal cells/mesenchymal stem cells from death cytokines such as FasL. Tissue Eng A2013; 19: 1972–83.
49.
DeckerTLohmann-MatthesMLKarckUPetersTDeckerK. Comparative study of cytotoxicity, tumor necrosis factor, and prostaglandin release after stimulation of rat Kupffer cells, murine Kupffer cells, and murine inflammatory liver macrophages. J Leukoc Biol1989; 45: 139–46.
50.
GardnerCRWassermanAJLaskinDL. Differential sensitivity of tumor targets to liver macrophage-mediated cytotoxicity. Cancer Res1987; 47: 6686–91.
SekiSHabuYKawamuraTTakedaKDobashiHOhkawaTHiraideH. The liver as a crucial organ in the first line of host defense: the roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag+ T cells in T helper 1 immune responses. Immunol Rev2000; 174: 35–46.
53.
SuWKitagawaTItoTOyamaTLeeCMKimYKMatsudaH. Antitumor effect to IL-12 administration into the portal vein on murine liver metastasis. J Hepato-Biliary-Pancreatic Surg2002; 9: 503–10.
54.
TimmersMVekemansKVermijlenDAsosinghKKuppenPBouwensLWisseEBraetF. Interactions between rat colon carcinoma cells and Kupffer cells during the onset of hepatic metastasis. Int J Cancer2004; 112: 793–802.
55.
YinglingJMBlanchardKLSawyerJS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov2004; 3: 1011–22.
56.
BayonLGIzquierdoMASirovichIvan RooijenNBeelenRHMeijerS. Role of Kupffer cells in arresting circulating tumor cells and controlling metastatic growth in the liver. Hepatology1996; 23: 1224–31.
57.
BirdNCMangnallDMajeedAW. Biology of colorectal liver metastases: a review. J Surg Oncol2006; 94: 68–80.
58.
WenSWAgerEIChristophiC. Bimodal role of Kupffer cells during colorectal cancer liver metastasis. Cancer Biol Ther2013; 14: 606–13.
59.
SosaMSBragadoPAguirre-GhisoJA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer2014; 14: 611–22.
60.
GiancottiFG. Mechanisms governing metastatic dormancy and reactivation. Cell2013; 155: 750–64.
61.
GhajarCMPeinadoHMoriHMateiIREvasonKJBrazierHAlmeidaDKollerAHajjarKAStainierDYChenEILydenDBissellMJ. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol2013; 15: 807–17.
62.
ThomasPHayashiHZimmerRForseRA. Regulation of cytokine production in carcinoembryonic antigen stimulated Kupffer cells by beta-2 adrenergic receptors: implications for hepatic metastasis. Cancer Lett2004; 209: 251–7.
63.
KnittelTMehdeMKoboldDSaileBDinterCRamadoriG. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. J Hepatol1999; 30: 48–60.
64.
GordenDLFingletonBCrawfordHCJansenDELepageMMatrisianLM. Resident stromal cell-derived MMP-9 promotes the growth of colorectal metastases in the liver microenvironment. Int J Cancer2007; 121: 495–500.
65.
KangNGoresGJShahVH. Hepatic stellate cells: partners in crime for liver metastases?Hepatology2011; 54: 707–13.
66.
OlasoESantistebanABidaurrazagaJGressnerAMRosenbaumJVidal-VanaclochaF. Tumor-dependent activation of rodent hepatic stellate cells during experimental melanoma metastasis. Hepatology1997; 26: 634–42.
67.
AmannTBatailleFSprussTMuhlbauerMGabeleEScholmerichJKieferPBosserhoffAKHellerbrandC. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci2009; 100: 646–53.
68.
MazzoccaACoppariRDe FrancoRChoJYLibermannTAPinzaniMTokerA. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res2005; 65: 4728–38.
69.
OkabeHBeppuTHayashiHIshikoTMasudaTOtaoRHorladHJonoHUedaMPhdSSAndoYBabaH. Hepatic stellate cells accelerate the malignant behavior of cholangiocarcinoma cells. Ann Surg Oncol2011; 18: 1175–84.
70.
ZhaoWZhangLYinZSuWRenGZhouCYouJFanJWangX. Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice. Int J Cancer2011; 129: 2651–61.
71.
ShimizuSYamadaNSawadaTIkedaKKawadaNSekiSKanedaKHirakawaK. In vivo and in vitro interactions between human colon carcinoma cells and hepatic stellate cells. Jpn J Cancer Res2000; 91: 1285–95.
72.
MatsusueRKuboHHisamoriSOkoshiKTakagiHHidaKNakanoKItamiAKawadaKNagayamaSSakaiY. Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis. Ann Surg Oncol2009; 16: 2645–53.
73.
MussoOTheretNCampionJPTurlinBMilaniSGrapponeCClementB. In situ detection of matrix metalloproteinase-2 (MMP2) and the metalloproteinase inhibitor TIMP2 transcripts in human primary hepatocellular carcinoma and in liver metastasis. J Hepatol1997; 26: 593–605.
74.
TheretNMussoOCampionJPTurlinBLorealOL’Helgoualc’hAClementB. Overexpression of matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 in liver from patients with gastrointestinal adenocarcinoma and no detectable metastasis. Int J Cancer1997; 74: 426–32.
75.
HautekeeteMLGeertsA. The hepatic stellate (Ito) cell: its role in human liver disease. Virchows Archiv1997; 430: 195–207.
76.
KlieveriLFehresOGriffiniPVan NoordenCJFrederiksWM. Promotion of colon cancer metastases in rat liver by fish oil diet is not due to reduced stroma formation. Clin Exp Metastasis2000; 18: 371–7.
77.
TeradaTMakimotoKTerayamaNSuzukiYNakanumaY. Alpha-smooth muscle actin-positive stromal cells in cholangiocarcinomas, hepatocellular carcinomas and metastatic liver carcinomas. J Hepatol1996; 24: 706–12.
78.
EvenoCHainaudPRampanouABonninPBakhoucheSDupuyEContreresJOPocardM. Proof of prometastatic niche induction by hepatic stellate cells. J Surg Res2015; 194: 496–504.
79.
OlasoESaladoCEgilegorEGutierrezVSantistebanASancho-BruPFriedmanSLVidal-VanaclochaF. Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology2003; 37: 674–85.
80.
TauraKDe MinicisSSekiEHatanoEIwaisakoKOsterreicherCHKodamaYMiuraKIkaiIUemotoSBrennerDA. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology2008; 135: 1729–38.
81.
TorimuraTSataMUenoTKinMTsujiRSuzakuKHashimotoOSugawaraHTanikawaK. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol1998; 29: 986–91.
82.
TorimuraTUenoTKinMHaradaRTaniguchiENakamuraTSakataRHashimotoOSakamotoMKumashiroRSataMNakashimaOYanoHKojiroM. Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol2004; 40: 799–807.
83.
ChenCHKuoLMChangYWuWGoldbachCRossMAStolzDBChenLFungJJLuLQianS. In vivo immune modulatory activity of hepatic stellate cells in mice. Hepatology2006; 44: 1171–81.
84.
CorpechotCBarbuVWendumDKinnmanNReyCPouponRHoussetCRosmorducO. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology2002; 35: 1010–21.
85.
SemelaDDasALangerDKangNLeofEShahV. Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function. Gastroenterology2008; 135: 671–9.
86.
WirzWAntoineMTagCGGressnerAMKorffTHellerbrandCKieferP. Hepatic stellate cells display a functional vascular smooth muscle cell phenotype in a three-dimensional co-culture model with endothelial cells. Differ Res Biol Divers2008; 76: 784–94.
87.
YuMCChenCHLiangXWangLGandhiCRFungJJLuLQianS. Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology2004; 40: 1312–21.
88.
RoosEDingemansKPVan de PavertIVVan den Bergh-WeermanMA. Mammary-carcinoma cells in mouse liver: infiltration of liver tissue and interaction with Kupffer cells. Br J Cancer1978; 38: 88–99.
89.
RoosEVan de PavertIVMiddelkoopOP. Infiltration of tumour cells into cultures of isolated hepatocytes. J Cell Sci1981; 47: 385–97.
90.
MookORvan MarleJJongesRVreeling-SindelarovaHFrederiksWMVan NoordenCJ. Interactions between colon cancer cells and hepatocytes in rats in relation to metastasis. J Cell Mol Med2008; 12: 2052–61.
91.
MookORVan MarleJVreeling-SindelarovaHJongesRFrederiksWMVan NoordenCJ. Visualization of early events in tumor formation of eGFP-transfected rat colon cancer cells in liver. Hepatology2003; 38: 295–304.
92.
TabariesSDupuyFDongZMonastAAnnisMGSpicerJFerriLEOmerogluABasikMAmirEClemonsMSiegelPM. Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. Mol Cell Biol2012; 32: 2979–91.
93.
ElzagheidAAlgarsABendardafRLamlumHRistamakiRCollanYSyrjanenKPyrhonenS. E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome. World J Gastroenterol2006; 12: 4304–9.
94.
KowalskiPJRubinMAKleerCG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res2003; 5: R217–22.
95.
YatesCCShepardCRStolzDBWellsA. Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br J Cancer2007; 96: 1246–52.
96.
ChaoYWuQShepardCWellsA. Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance. Clin Exp Metastasis2012; 29: 39–50.
97.
LiMAliottaJMAsaraJMWuQDoonerMSTuckerLDWellsAQuesenberryPJRamratnamB. Intercellular transfer of proteins as identified by stable isotope labeling of amino acids in cell culture. J Biol Chem2010; 285: 6285–97.
98.
Luebke-WheelerJLNedredalGYeeLAmiotBPNybergSL. E-cadherin protects primary hepatocyte spheroids from cell death by a caspase-independent mechanism. Cell Transplant2009; 18: 1281–7.
99.
HackamDGRedelmeierDA. Translation of research evidence from animals to humans. JAMA2006; 296: 1731–2.
100.
MestasJHughesCC. Of mice and not men: differences between mouse and human immunology. J Immunol2004; 172: 2731–8.
101.
FantozziAChristoforiG. Mouse models of breast cancer metastasis. Breast Cancer Res2006; 8: 212–212.
102.
KhannaCHunterK. Modeling metastasis in vivo. Carcinogenesis2005; 26: 513–23.
103.
TeicherBA. Tumor models for efficacy determination. Mol Cancer Ther2006; 5: 2435–43.
104.
JunttilaMRde SauvageFJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature2013; 501: 346–54.
105.
SlaneyCYRautelaJParkerBS. The emerging role of immunosurveillance in dictating metastatic spread in breast cancer. Cancer Res2013; 73: 5852–7.
106.
WikswoJP. The relevance and potential roles of microphysiological systems in biology and medicine. Exp Biol Med2014; 239: 1061–72.
VernettiLASenutovitchNBoltzRDeBiasioRYing ShunTGoughATaylorDL. A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Exp Biol Med2016; 241: 101–14.
109.
VillasanteAVunjak-NovakovicG. Tissue-engineered models of human tumors for cancer research. Expert Opin Drug Discov2015; 10: 257–68.
110.
WheelerSEBorensteinJTClarkAMEbrahimkhaniMRFoxIJGriffithLInmanWLauffenburgerDNguyenTPillaiVCPrantil-BaunRStolzDBTaylorDUlrichTVenkataramananRWellsAYoungC. All-human microphysical model of metastasis therapy. Stem Cell Res Ther2013; 4: S11–S11.
111.
BenamKHDauthSHassellBHerlandAJainAJangKJKaralisKKimHJMacQueenLMahmoodianRMusahSTorisawaYSvan der MeerADVillenaveRYadidMParkerKKIngberDE. Engineered in vitro disease models. Annu Rev Pathol2015; 10: 195–262.
112.
SenutovitchNVernettiLBoltzRDeBiasioRGoughATaylorDL. Fluorescent protein biosensors applied to microphysiological systems. Exp Biol Med2015; 240: 795–808.
BaleSSVernettiLSenutovitchNJindalRHegdeMGoughAMcCartyWJBakanABhushanAShunTYGolbergIDeBiasioRUstaOBTaylorDLYarmushML. In vitro platforms for evaluating liver toxicity. Exp Biol Med2014; 239: 1180–91.
115.
EbrahimkhaniMRNeimanJARaredonMSHughesDJGriffithLG. Bioreactor technologies to support liver function in vitro. Adv Drug Deliv Rev2014; 69–70: 132–57.
116.
ClarkAMWheelerSETaylorDPPillaiVCYoungCLPrantil-BaunRNguyenTStolzDBBorensteinJTLauffenburgerDAVenkataramananRGriffithLGWellsA. A microphysiological system model of therapy for liver micrometastases. Exp Biol Med2014; 239: 1170–9.
117.
DomanskyKInmanWSerdyJDashALimMHGriffithLG. Perfused multiwell plate for 3D liver tissue engineering. Lab Chip2010; 10: 51–8.
118.
YatesCShepardCRPapworthGDashABeer StolzDTannenbaumSGriffithLWellsA. Novel three-dimensional organotypic liver bioreactor to directly visualize early events in metastatic progression. Adv Cancer Res2007; 97: 225–46.
119.
WheelerSEClarkAMTaylorDPYoungCLPillaiVCStolzDBVenkataramananRLauffenburgerDGriffithLWellsA. Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system. Br J Cancer2014; 111: 2342–50.
120.
LeePJHungPJLeeLP. An artificial liver sinusoid with a microfluidic endothelial-like barrier for primary hepatocyte culture. Biotechnol Bioeng2007; 97: 1340–6.
121.
ZhangMYLeePJHungPJJohnsonTLeeLPMofradMR. Microfluidic environment for high density hepatocyte culture. Biomed Microdevices2008; 10: 117–21.
122.
LeePAllenMHungPChapter 14—Microfluidic hepatotoxicity platform A2—Bettinger, Christopher. In: BorensteinJTTaoSL (eds). Microfluidic cell culture systems, Oxford: William Andrew Publishing, 2013, pp. 341–55.
123.
ChaoPMaguireTNovikEChengKCYarmushML. Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. Biochem Pharmacol2009; 78: 625–32.
124.
NovikEMaguireTJChaoPChengKCYarmushML. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem Pharmacol2010; 79: 1036–44.
125.
KingPDPerryMC. Hepatotoxicity of chemotherapy. Oncologist2001; 6: 162–76.
